Staphylococcus aureus FabI: Inhibition, Substrate Recognition, and Potential Implications for In Vivo Essentiality
- 9 May 2012
- journal article
- Published by Elsevier BV in Structure
- Vol. 20 (5), 802-813
- https://doi.org/10.1016/j.str.2012.03.013
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitorsProceedings of the National Academy of Sciences of the United States of America, 2011
- A Medicinal Chemist’s Guide to Molecular InteractionsJournal of Medicinal Chemistry, 2010
- Antibiotics for Emerging PathogensScience, 2009
- Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coliNature Chemical Biology, 2009
- Slow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis: Residence Time and in Vivo ActivityACS Chemical Biology, 2009
- Design and Synthesis of Aryl Ether Inhibitors of the Bacillus Anthracis Enoyl‐ACP ReductaseChemMedChem, 2008
- Crystal structure and substrate specificity of the β‐ketoacyl‐acyl carrier protein synthase III (FabH) from Staphylococcus aureusProtein Science, 2005
- Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensionsActa Crystallographica Section D-Biological Crystallography, 2004
- ESPript: analysis of multiple sequence alignments in PostScript.Bioinformatics, 1999
- Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical featuresPeptide Science, 1983